| UniProt/SwissProt ID: | FUBP1_HUMAN |
| Description: | far upstream element (FUSE) binding protein 1 [Source:HGNC Symbol;Acc:4004] |
| Location: | chr1 p31.1 |
| Node attribute: | substrate; TF |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| S99 | QQQSRsVMTEE | HPRD | |
| S52 | GDAGTsLNSND | PhosphoSitePlus; HPRD | |
| S84 | APQNDsFGTQL | PhosphoSitePlus; HPRD | |
| Y619 | AWAEYyRQQAA | DUF1897 | PhosphoSitePlus |
| S55 | GTSLNsNDYGY | HPRD | |
| Y60 | SNDYGyGGQKR | PhosphoSitePlus | |
| Y268 | EVRNEyGSRIG | PhosphoSitePlus | |
| Y4 | __MADySTVPP | PhosphoSitePlus | |
| S630 | YYAQTsPQGMP | PhosphoSitePlus; HPRD; phosphoELM; SysPTM | |
| T229 | DGPQNtGADKP | KH_1 | PhosphoSitePlus |
| S140 | QIAPDsGGLPE | HPRD; phosphoELM | |
| S270 | RNEYGsRIGGN | PhosphoSitePlus | |
| Y618 | AAWAEyYRQQA | DUF1897 | PhosphoSitePlus |
| T229 | DGPQNtGADKP | HPRD | |
| T207 | GKGGEtIKQLQ | KH_1 | PhosphoSitePlus |
| Y58 | LNSNDyGYGGQ | PhosphoSitePlus; HPRD; phosphoELM | |
| Y589 | KAWEEyYKKMG | PhosphoSitePlus | |
| S140 | QIAPDsGGLPE | KH_1 | PhosphoSitePlus |
| T153 | CMLTGtPESVQ | KH_1 | PhosphoSitePlus; SysPTM |
| T153 | CMLTGtPESVQ | HPRD; phosphoELM; SysPTM | |
| T207 | GKGGEtIKQLQ | HPRD | |
| S156 | TGTPEsVQSAK | KH_1 | PhosphoSitePlus |
| Y626 | QQAAYyAQTSP | PhosphoSitePlus; HPRD | |
| Y242 | ITGDPyKVQQA | KH_1 | PhosphoSitePlus |
| T398 | GKGGEtIKSIS | KH_1 | PhosphoSitePlus |
| Y4 | TVPP | HPRD | |
| T629 | AYYAQtSPQGM | PhosphoSitePlus; HPRD; SysPTM | |
| Y625 | RQQAAyYAQTS | PhosphoSitePlus; HPRD | |
| Dephosphorylation site |
| FUBP1_HUMAN do not have dephosphorylation site. |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000359804 | P281L | COSMIC | Central Nervous System Neoplasms | 18772396 | ENSP00000359804 | H463fs*>182 | COSMIC | Central Nervous System Neoplasms | 21817013 | ENSP00000359804 | Q548* | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000359804 | E445* | COSMIC | Central Nervous System Neoplasms | 21817013 | ENSP00000359804 | E411* | COSMIC | Central Nervous System Neoplasms | 21817013 | ENSP00000359804 | D570fs*>75 | COSMIC | Central Nervous System Neoplasms | 21817013 | ENSP00000359804 | A596T | COSMIC | Central Nervous System Neoplasms | 18772396 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000359804 | Gastric Cancer | Metastasis | cell line | Down | 0.69 | 17022644 | ENSP00000359804 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 2.9 | 15759316 | ENSP00000359804 | Leukemia | Normal vs. Cancer | cell line | Down | 0.47 | 17022645 | ENSP00000359804 | Leukemia | Normal vs. Cancer | cell line | Down | 0.47 | 17022645 | ENSP00000359804 | Lung Cancer | Treatment (none vs. FK228 treatment) | cell line | Down | 18549279 | ENSP00000359804 | Breast Cancer | Treatment (none vs. 17b-Estradiol treatment) | cell line | Up | 2.4 | 18491314 | ENSP00000359804 | hepatitis B virus | Normal vs. Cancer | tissue | Up | 3.6 | 19003864 | ENSP00000359804 | Lung Cancer | Treatment(none vs 20 mg/mL GTE treatment) | cell line | Up | 5.5 | 19137550 | ENSP00000359804 | Lung Cancer | Treatment(none vs 40 mg/mL GTE treatment) | cell line | Up | 6.3 | 19137550 | ENSP00000359804 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.2 | 20804217 | ENSP00000359804 | Gastric Cancer | Metastasis | cell line | Down | 0.69 | 17022644 | ENSP00000359804 | chronic myeloid leukemia | Treatment (Imatinib-sensitive vs. Imatinib-resistant) | cell line | Down | 20417730 | ENSP00000359804 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.06 | 17655343 | ENSP00000359804 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.09 | 17655343 | ENSP00000359804 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.12 | 17655343 | ENSP00000359804 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.07 | 17655343 | ENSP00000359804 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.09 | 17655343 | ENSP00000359804 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.18 | 17655343 | ENSP00000359804 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 17655343 | ENSP00000359804 | Ovarian Cancer | Metastasis | cell line | Up | 17892554 | ENSP00000359804 | Biliary Tract Cancer | Metastasis | cell line | Up | 3.1 | 19299076 | ENSP00000359804 | Pancreatic Cancer | Treatment (Gemcitabine-sensitive vs. Gemcitabine-resistant) | cell line | Down | 0.4 | 20944110 |
| Hyperphosphorylation site |
| FUBP1_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| M3K7_HUMAN | FUBP1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| FUBP1_HUMAN | MYC_HUMAN | TF -> target gene | TRANSFAC |
| Function Annotation |
| KEGG Pathway |
| FUBP1_HUMAN is not in KEGG pathway. |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0003697 | single-stranded DNA binding | TAS | molecular_function |
| GO:0003723 | RNA binding | IEA | molecular_function |
| GO:0003700 | sequence-specific DNA binding transcription factor | TAS | molecular_function |
| GO:0006366 | transcription from RNA polymerase II promoter | TAS | biological_process |
| GO:0005634 | nucleus | IDA | cellular_component |
| GO:0010628 | positive regulation of gene expression | IDA | biological_process |
| GO:0005515 | protein binding | IEA | molecular_function |